Strides Pharma divests stake in Pivot Path for ₹100 crore
after close1 source ↓written by the desknot a recommendation
- Ascent Capital
- ₹100 crore
Strides Pharma Science has announced the divestment of its stake in Pivot Path to Ascent Capital for ₹100 crore. This strategic move aims to enhance its balance sheet while focusing on specialized CDMO and formulation businesses. The transaction underscores the growing interest from private equity in the pharmaceutical sector.
• Transaction Value: ₹100 crore
• Counterparty: Ascent Capital Group
• Sector: Pharmaceuticals / Health-Tech
This divestment may signal a shift in investment strategies within the sector, attracting more private equity interest.
Not investment advice. For informational purposes only.